The decreased tumor size and enhanced tumor rejection in DGKζ - deficient mice indirectly suggests that enhanced Erk signaling may be superior to enhanced NF - κΒ activation in facilitating T cell activity against tumor, especially because DKO mice did not exhibit improved tumor control relative to DGKζ − / − mice.
After five weeks, the combination treatment in the six mice
decreased tumor size by up to 66 percent, compared with six mice treated with only paclitaxel.
In fact, a single dose
decreased tumor size by 60 percent over a three - week period.
Not exact matches
While Paclitaxel treatment alone can lead to a
decrease in
tumor size, there is a large risk of relapse once the treatment is terminated.
The researchers report that 62 % had an overall response to the drug combination, meaning that their
tumors decreased in
size.
Tumor size in mice injected with the antibody steadily
decreased over time, while their survival increased.
In six of the 13 patients, all
tumors decreased in
size by at least 50 %.
The importance of stromal POSTN was also demonstrated in another study in which orthotopic inoculation of gastric cancer cells into Rag2 − / −; Postn − / − mice reduced
tumor size,
decreased invasiveness, and
decreased growth compared to Rag2 − / −; Postn + / + mice (Kikuchi et al., 2014).
In similar patients enrolled in a previous national trial,
tumor size decreased in only 40 percent of patients treated with the same drugs but without hu14.18 K322A.
Tumor sizes decreased in the treated mice, areas of cell death were visible, and all AAV2 treated mice survived through the study, a direct contrast to the untreated mice.
Now, in a new study in the journal Cancer Cell, Shaw and a team of scientists at the Salk Institute for Biological Studies found that phenformin, a derivative of the widely - used diabetes drug metformin,
decreased the
size of lung
tumors in mice and increased the animals» survival.
It is defined as a
decrease of ≥ 50 % in the total
tumor size and / or total number of
tumors since the start of the trial.
Partial response, commonly referred to as PR, is a partial
decrease in the
size of a cancerous
tumor or a
decrease in the total number of cancer lesions.
Importantly, an inverse correlation was observed for ER - α — negative lines with a
decrease in the proportion of MFC within the xenograft as
tumor size increases (Fig. 5Bii).
GSP inhibited skin
tumor formation and
decreased the
size of skin
tumors in hairless mice exposed to carcinogenic UV radiation.
Under normal conditions, the
tumors would
decrease in
size following the administration of chemotherapy.
Decreases in
tumor size that lasted for a minimum of six months were seen in about 16 percent of patients who received Imlygic, compared with about 2 percent of those who received the other treatment, the findings showed.
In other cases, the goal may be to
decrease the
size of the
tumor and reduce pain.
It can help reduce the
size of a solid
tumor (lymphosarcoma) and
decrease the number of circulating cancerous cells in a cat with leukemia.